A Jatoi

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Rash from EGFR inhibitors: opportunities and challenges for palliation
    Benjamin M Solomon
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 10:304-8. 2008
  2. pmc Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Cancer Manag Res 1:61-8. 2009
  3. pmc Asphyxiation with a fentanyl patch
    Aaron S Mansfield
    Division of Medical Oncology, Mayo Clinic, Rochester, Minn, USA
    Case Rep Oncol 6:242-4. 2013
  4. pmc Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy
    Tamana Walia
    Division of Medical Oncology, Rochester, MN, USA
    Ther Clin Risk Manag 4:1363-6. 2008
  5. ncbi request reprint Incidence and outcomes of chemotherapy and radiation in morbidly obese patients with locally advanced lung and esophageal cancers: a single-institution experience
    Krishna Patel
    Department of Oncology and Cancer Education Program, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Control 21:63-6. 2014
  6. ncbi request reprint Cancer chemotherapy: with or without food?
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 18:S13-6. 2010
  7. pmc A pilot study of long-acting octreotide for symptomatic malignant ascites
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Oncology 82:315-20. 2012
  8. pmc The positive impact of a facilitated peer mentoring program on academic skills of women faculty
    Prathibha Varkey
    Division of Preventive and Occupational Medicine and Department of Medicine, Mayo Clinic, Rochester, MN, USA
    BMC Med Educ 12:14. 2012
  9. doi request reprint The purported effects of alcohol on appetite and weight in lung cancer patients
    Aminah Jatoi
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Nutr Cancer 63:1251-5. 2011
  10. ncbi request reprint A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:1396-403. 2007

Research Grants

  1. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
  2. Wine for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2010
  3. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
  4. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
  5. Wine for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2007
  6. Wine for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2009

Detail Information

Publications102 found, 100 shown here

  1. ncbi request reprint Rash from EGFR inhibitors: opportunities and challenges for palliation
    Benjamin M Solomon
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Oncol Rep 10:304-8. 2008
    ..This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment...
  2. pmc Is social support associated with improved clinical outcomes in geriatric lung cancer patients? Observations from North Central Cancer Treatment Group Studies N9921 and N0222
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Cancer Manag Res 1:61-8. 2009
    ..This study explored the extent of social support and its potential association with survival and adverse events in geriatric lung cancer patients...
  3. pmc Asphyxiation with a fentanyl patch
    Aaron S Mansfield
    Division of Medical Oncology, Mayo Clinic, Rochester, Minn, USA
    Case Rep Oncol 6:242-4. 2013
    ..The transdermal delivery of fentanyl may lead to unusual, unanticipated complications. Herein, we describe a fentanyl patch complication, which, to our knowledge, has not been previously reported...
  4. pmc Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy
    Tamana Walia
    Division of Medical Oncology, Rochester, MN, USA
    Ther Clin Risk Manag 4:1363-6. 2008
    ..Do colorectal cancer patients with hyperbilirubinemia and liver metastases benefit from chemotherapy?..
  5. ncbi request reprint Incidence and outcomes of chemotherapy and radiation in morbidly obese patients with locally advanced lung and esophageal cancers: a single-institution experience
    Krishna Patel
    Department of Oncology and Cancer Education Program, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Control 21:63-6. 2014
    ..This guideline does not address dosages for patients who are morbidly obese (body mass index ≥ 40) and receiving concomitant chemotherapy and radiation...
  6. ncbi request reprint Cancer chemotherapy: with or without food?
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 18:S13-6. 2010
    ..Over the past few years, new chemotherapy agents have emerged, and several are oral. This review attempts to highlight the challenges associated with the interactions between food and chemotherapy, both oral and intravenous...
  7. pmc A pilot study of long-acting octreotide for symptomatic malignant ascites
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Oncology 82:315-20. 2012
    ..This trial explored whether octreotide, an inhibitor of vascular endothelial growth factor, a putative mediator of ascites, prolongs the interval to next paracentesis...
  8. pmc The positive impact of a facilitated peer mentoring program on academic skills of women faculty
    Prathibha Varkey
    Division of Preventive and Occupational Medicine and Department of Medicine, Mayo Clinic, Rochester, MN, USA
    BMC Med Educ 12:14. 2012
    ..We describe a facilitated peer mentoring program in our institution's department of medicine...
  9. doi request reprint The purported effects of alcohol on appetite and weight in lung cancer patients
    Aminah Jatoi
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Nutr Cancer 63:1251-5. 2011
    ..This report suggests a need for further study of alcohol as a palliative agent for cancer-associated loss of appetite and weight...
  10. ncbi request reprint A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 110:1396-403. 2007
    ....
  11. ncbi request reprint A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Urology 69:289-94. 2007
    ..Tomatoes are rich in lycopene. This study explored the efficacy of a lycopene-rich tomato product in androgen-independent prostate cancer and the reasons patients participated in an "alternative medicine" study...
  12. ncbi request reprint Interleukin-1 genetic polymorphisms and their relationship to the cancer anorexia/weight loss syndrome in metastatic gastric and gastroesophageal junction adenocarcinoma
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    J Support Oncol 5:41-6. 2007
    ..These preliminary data suggest that certain interleukin-1 beta genetic polymorphisms may modulate the cancer anorexia/weight loss syndrome in patients with metastatic gastric and esophageal cancer. Confirmatory studies are warranted...
  13. ncbi request reprint Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approach
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 4:499-502. 2006
    ..Patients may also benefit from appetite stimulants such as corticosteroids and progestational agents,and this review summarizes the benefits of using these agents as well as their contraindications...
  14. ncbi request reprint The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer
    A Jatoi
    The Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 19:241-7. 2006
    ..The proteolysis-inducing factor in urine does not appear to be tied to weight loss, anorexia, tumor response, or patient survival in the clinical setting of metastatic gastric/esophageal cancer...
  15. ncbi request reprint Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 23:9113-9. 2005
    ..To answer the question, "should elderly non-small-cell lung cancer patients be offered elderly-specific trials?"..
  16. ncbi request reprint Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group
    A Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:29-34. 2006
    ..We therefore undertook this phase II study to test this first-line combination in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia...
  17. ncbi request reprint Omega-3 fatty acid supplements for cancer-associated weight loss
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905 0002, USA
    Nutr Clin Pract 20:394-9. 2005
    ..This review includes a discussion of how these data might be interpreted and explained to cancer patients who are striving to cope with this syndrome...
  18. ncbi request reprint Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 30:507-13. 2007
    ..This study tested a 3-drug, multimodality approach. Chemotherapy dose reductions, the addition of amifostine, and pharmacogenetics were tested in an effort to mitigate toxicity and predict outcomes...
  19. ncbi request reprint Fish oil, lean tissue, and cancer: is there a role for eicosapentaenoic acid in treating the cancer anorexia/weight loss syndrome?
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Crit Rev Oncol Hematol 55:37-43. 2005
    ....
  20. doi request reprint Does marital status impact survival and quality of life in patients with non-small cell lung cancer? Observations from the mayo clinic lung cancer cohort
    Aminah Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Oncologist 12:1456-63. 2007
    ..Previous studies have found that marriage is associated with longer survival and better quality of life among lung cancer patients. The present study used the Mayo Clinic Lung Cancer Cohort to re-examine this issue...
  21. ncbi request reprint Bortezomib, paclitaxel, and carboplatin as a first-line regimen for patients with metastatic esophageal, gastric, and gastroesophageal cancer: phase II results from the North Central Cancer Treatment Group (N044B)
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Thorac Oncol 3:516-20. 2008
    ....
  22. ncbi request reprint Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)
    Aminah Jatoi
    Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 113:847-53. 2008
    ..Epidermal growth factor receptor (EGFR) inhibitors are effective cancer therapies, but they are reported to cause a rash in >50% of patients. In the current study, the authors examined the use of tetracycline for rash prevention...
  23. pmc Is Spanish language a barrier to domestic violence assessment?
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Womens Health (Larchmt) 20:1111-6. 2011
    ..This study tested the hypothesis that language does, in fact, pose a barrier to screening and that Spanish-speaking women report lower lifetime screening rates...
  24. doi request reprint Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors
    Aminah Jatoi
    Department of Oncology, Mayo Clinic Rochester, Rochester, Minnesota 55905, USA
    J Thorac Oncol 5:1994-8. 2010
    ..Based on favorable preliminary clinical data and the need to identify effective, well-tolerated neoadjuvant regimens for patients with locally advanced esophageal cancer, this clinical trial was undertaken...
  25. doi request reprint Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)
    Aminah Jatoi
    Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 19:1601-7. 2011
    ..Previous studies suggest tetracycline and other antibiotics lessen the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm such findings...
  26. pmc A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422)
    A Jatoi
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Ann Oncol 21:2040-4. 2010
    ..Non-small-cell lung cancer (NSCLC) is a disease of the elderly. Seeking a tolerable but effective regimen, we tested cetuximab + radiation in elderly and/or poor performance status patients with locally advanced NSCLC...
  27. ncbi request reprint Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials
    Aminah Jatoi
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Oncol 36:601-6. 2010
    ..Although age should not preclude trial entry, these adverse event rates suggest a need to develop more tolerable regimens for older patients with these malignancies...
  28. pmc The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer
    Aminah Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Support Care Cancer 18:1299-304. 2010
    ....
  29. doi request reprint A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)
    Aminah Jatoi
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Lung Cancer 68:234-9. 2010
    ....
  30. pmc Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147
    Aminah Jatoi
    Mayo Clinic, Rochester, MN 55905, USA
    Oncology 77:120-3. 2009
    ..The objective of this study was to identify clinical predictors of severe rash in the hope of utilizing such factors in the design of future rash palliative and prevention trials...
  31. ncbi request reprint Side effects and pharmaceutical company bias: adverse event reporting in cancer supportive and palliative care trials
    Aminah Jatoi
    Mayo Clinic, Departments of Oncology, 200 First Street SW, Rochester, Minnesota 55905, USA
    Expert Opin Investig Drugs 17:1787-90. 2008
    ....
  32. doi request reprint Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Oncologist 13:1201-4. 2008
    ..It suggests that quality of life issues should remain at the forefront as cancer patients and health care providers make decisions about holding cancer therapy...
  33. ncbi request reprint Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group
    Aminah Jatoi
    Mayo Clinic, Rochester, MN, 55905, USA
    Support Care Cancer 13:381-6. 2005
    ..The recent emergence of bortezomib, a proteasome inhibitor, now allows testing on whether proteasome inhibition is effective therapy for cancer-associated weight loss...
  34. ncbi request reprint Exploring vitamin and mineral supplementation and purported clinical effects in patients with small cell lung cancer: results from the Mayo Clinic lung cancer cohort
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nutr Cancer 51:7-12. 2005
    ..These data suggest an association between vitamin/mineral supplementation and improved survival and point to a need for future studies on vitamin and mineral supplementation in small cell lung cancer patients...
  35. ncbi request reprint Folate status among patients with non-small cell lung cancer: a case-control study
    A Jatoi
    Division of Hematology Oncology, Department of Medicine, New England Medical Center, Tufts University, Boston, MA, USA
    J Surg Oncol 77:247-52. 2001
    ..This case control study explored the purported inverse relationship between folate status and lung cancer development...
  36. ncbi request reprint Neuropeptide Y, leptin, and cholecystokinin 8 in patients with advanced cancer and anorexia: a North Central Cancer Treatment Group exploratory investigation
    A Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 92:629-33. 2001
    ..Anorexia is a noxious symptom, and over half of patients with advanced cancer experience it. Neuropeptide Y (NPY), leptin, and cholecystokinin 8 (CCK8) have been implicated...
  37. ncbi request reprint Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?
    A Jatoi
    Department of Medicine, The New England Medical Center, Tufts University, Boston, Massachusetts, USA
    Ann Thorac Surg 72:348-51. 2001
    ..This increase in REE leads to weight loss, which in turn confers a poor prognosis. This study was undertaken to determine whether the cancer cachexia syndrome occurs in patients with nonmetastatic NSCLC...
  38. ncbi request reprint An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort
    Aminah Jatoi
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:2469-76. 2004
    ..This study determined whether an EPA supplement-administered alone or with megestrol acetate (MA)-was more effective than MA...
  39. ncbi request reprint Does megestrol acetate down-regulate interleukin-6 in patients with cancer-associated anorexia and weight loss? A North Central Cancer Treatment Group investigation
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Support Care Cancer 10:71-5. 2002
    ..Our investigation provides no evidence that megestrol acetate down-regulates IL-6 in patients with cancer-associated anorexia and weight loss...
  40. ncbi request reprint Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:567-73. 2002
    ..To determine whether dronabinol administered alone or with megestrol acetate was more, less, or equal in efficacy to single-agent megestrol acetate for palliating cancer-associated anorexia...
  41. pmc Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4)
    Aminah Jatoi
    Mayo Clinic Foundation, Rochester, Minnesota 55905, USA
    Oncologist 15:1016-22. 2010
    ..Rash occurs in >50% of patients prescribed epidermal growth factor receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen prevents or mitigates these rashes...
  42. ncbi request reprint A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer 97:1442-6. 2003
    ..This Phase II trial explored green tea's antineoplastic effects in patients with androgen independent prostate carcinoma...
  43. ncbi request reprint Why should we care about the cancer anorexia/weight loss syndrome?
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 17:5-6. 2003
  44. ncbi request reprint A phase II study of topical ceramides for cutaneous breast cancer
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Breast Cancer Res Treat 80:99-104. 2003
    ..Short chain ceramides induce tumor cell apoptosis in preclinical models. Limited therapeutic options for patients with cutaneous breast cancer prompted the testing of these sphingolipids in patients with this disease...
  45. ncbi request reprint Daily activities: exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 11:460-4. 2003
    ..to describe the daily activities of older patients as they undergo chemotherapy for incurable metastatic lung cancer...
  46. ncbi request reprint A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Gastrointest Cancer 32:115-23. 2002
    ..With the emergence of data to suggest that single agent docetaxel and irinotecan carry antineoplastic effects in this setting, we determined the response rate of these agents when given in combination...
  47. ncbi request reprint Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer. A multi-institutional study from the North Central Cancer Treatment Group
    A Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Dis Esophagus 17:292-6. 2004
    ..Fourth, dysphagia was not associated with appetite, leptin or neuropeptide y. This study helps to dispel these four 'myths' and underscores the need for further quality of life research on dysphagia...
  48. ncbi request reprint The prognostic effect of increased resting energy expenditure prior to treatment for lung cancer
    A Jatoi
    Department of Medicine, The New England Medical Center, Tufts University, Boston, MA, USA
    Lung Cancer 23:153-8. 1999
    ..However, no study has validated this hypothesis to date. This study's objective was to examine the prognostic significance of REE in NSCLC...
  49. ncbi request reprint Investigating the utility of serum cytokine measurements in a multi-institutional cancer anorexia/weight loss trial
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905, USA
    Support Care Cancer 12:640-4. 2004
    ..As the translational component of a large multi-institutional trial, this study assessed the clinical value of serum concentrations of these cytokines in patients with this syndrome...
  50. ncbi request reprint Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer
    Aminah Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 2:323-34; discussion 334-7. 2004
    ..This review discusses the general approach to patients with ovarian cancer and inoperable malignant bowel obstruction, with an emphasis on such palliative strategies...
  51. ncbi request reprint A pilot study on safety and pharmacokinetics of infliximab for the cancer anorexia/weight loss syndrome in non-small-cell lung cancer patients
    Aminah Jatoi
    Division of Medical Oncology, Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 12:859-63. 2004
    ..The safety and pharmacokinetics of infliximab in combination with docetaxel, a commonly used chemotherapy agent for non-small-cell lung cancer, were explored in this pilot study...
  52. ncbi request reprint Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs
    Aminah Jatoi
    Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 13:66-9. 2005
    ..Because accrual was poor, this trial also offered opportunities for suggesting other study designs for future clinical trials on cognitive dysfunction in this group of patients...
  53. ncbi request reprint Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group
    K F Giordano
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Ann Oncol 17:652-6. 2006
    ..We therefore undertook this phase II study to test this combination in a multi-institutional, first-line clinical trial...
  54. pmc Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival
    James M Donahue
    Division of General Thoracic Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ann Thorac Surg 87:392-8; discussion 398-9. 2009
    ..Neoadjuvant chemoradiotherapy followed by esophagogastrectomy has become the standard of care for patients with locally advanced esophageal cancer. This report analyzes our experience with this treatment approach...
  55. ncbi request reprint Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institution
    Karin F Giordano
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 49:209-15. 2005
    ....
  56. doi request reprint Overall survival and self-reported fatigue in patients with esophageal cancer
    M C Stauder
    Department of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Support Care Cancer 21:511-9. 2013
    ..A prospective cohort study was conducted to analyze whether self-reported fatigue predicts overall survival in patients with esophageal cancer...
  57. ncbi request reprint A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients
    A Jatoi
    Department of Medicine, Tufts University and New England Medical Center, Boston, Massachusetts 02111, USA
    J Surg Oncol 68:231-6. 1998
    ..This cross-sectional study of postoperative non-small cell lung cancer (NSCLC) patients examined possible effects of vitamin intake and folate status on disease-free survival...
  58. ncbi request reprint A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies
    Cynthia Ma
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 59:207-15. 2007
    ..Two different treatment schedules of bortezomib in combination with paclitaxel and carboplatin were tested in this phase I study to evaluate the effects of scheduling on toxicities, pharmacodynamics and clinical activity...
  59. ncbi request reprint Is voluntary vitamin and mineral supplementation associated with better outcome in non-small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Lung Cancer 49:77-84. 2005
    ..The goal of this study was to determine whether vitamin/mineral supplementation is associated with improved survival and quality of life in a cohort of NSCLC patients...
  60. doi request reprint Weight loss in patients with advanced cancer: effects, causes, and potential management
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Support Palliat Care 2:45-8. 2008
    ..This review provides an update of such observations and places them within the context of previous work...
  61. ncbi request reprint Environmental tobacco smoke exposure in women with lung cancer
    M de Andrade
    Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Lung Cancer 43:127-34. 2004
    ..We report the patterns of ETS exposure history in a clinical cohort of women with newly diagnosed lung cancer...
  62. ncbi request reprint An update: cancer-associated anorexia as a treatment target
    A Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Clin Nutr Metab Care 4:179-82. 2001
    ..To date, however, palliative options remain limited. Megestrol acetate and dexamethasone provide only modest relief. Novel agents such as thalidomide, adenosine triphosphate, and other cytokine inhibitors merit further investigation...
  63. ncbi request reprint Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients
    Farrah Mateen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Clin Nutr 25:711-5. 2006
    ..This review focuses on these trials, summarizing their findings and providing a practical approach for prescribing megestrol acetate to advanced cancer patients who suffer from the cancer anorexia/weight loss syndrome...
  64. ncbi request reprint Current management of cancer-associated anorexia and weight loss
    A Jatoi
    Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 15:497-502, 508; discussion 508-10. 2001
    ....
  65. ncbi request reprint On appetite and its loss
    Aminah Jatoi
    Division of Medical Oncology and Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:79s-81s. 2003
  66. doi request reprint Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer
    Nisha L Jacobs
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Gastrointest Cancer 40:46-50. 2009
    ..As a result, few studies have focused on these patients' cumulative, cancer-related morbidity and late mortality. This descriptive study was undertaken to explore such issues...
  67. ncbi request reprint Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (>or=65 years of age): a phase II North Central Cancer Treatment Group study
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Clin Oncol 26:441-7. 2003
    ..However, the relatively mild toxicity profile observed in this trial suggests that this regimen might remain an option for patients at increased risk for myelosuppression or with a poor performance status...
  68. ncbi request reprint Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity
    Anne Kanard
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Lung Cancer 43:345-53. 2004
    ..This trial was conducted to determine the tumor response rate and toxicity profile of oral vinorelbine in advanced non-small cell lung cancer patients > or = 65 years of age...
  69. ncbi request reprint Pharmacological options for advanced cancer patients with loss of appetite and weight
    Deepti Behl
    Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
    Expert Opin Pharmacother 8:1085-90. 2007
    ..This article reviews data to support the use of these agents, discusses the findings of other more recent studies in this field and provides an overview of promising strategies that merit further investigation...
  70. ncbi request reprint The cancer anorexia/weight loss syndrome: therapeutic challenges
    Karin F Giordano
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Curr Oncol Rep 7:271-6. 2005
    ..As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge...
  71. ncbi request reprint A critical look at the role of chemotherapy in older patients with non-small cell lung cancer
    Aminah Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Thorac Oncol 2:83-90. 2007
    ....
  72. doi request reprint Marital status and quality of life in patients with esophageal cancer or Barrett's esophagus: the mayo clinic esophageal adenocarcinoma and Barrett's esophagus registry study
    Robert C Miller
    Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Dig Dis Sci 55:2860-8. 2010
    ..Patients with esophageal carcinoma (EC) report deficits in quality of life (QOL), depending on the extent of malignant disease and the goals of treatment at the time of QOL measurement...
  73. ncbi request reprint The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer
    Charles Y F Young
    Department of Urology, Mayo Medical Graduate School and Mayo Graduate School, Mayo Clinic Foundation, Rochester, Minnesota, 55905, USA
    Curr Med Chem 11:909-23. 2004
    ..We further discuss the potential implication of these dietary chemicals on prevention of development and progression of prostate cancer...
  74. ncbi request reprint The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:363-8. 2007
    ....
  75. ncbi request reprint The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly
    Steven E Schild
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    J Clin Oncol 21:3201-6. 2003
    ..No difference in survival was identified between the two arms. This secondary analysis was performed to examine the relationship between patient age and outcome...
  76. ncbi request reprint Can complementary and alternative medicine clinical cancer research be successfully accomplished? The Mayo Clinic-North Central Cancer Treatment Group experience
    Debra L Barton
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Soc Integr Oncol 4:143-52. 2006
    ..Well-designed and adequately powered studies can be implemented, and large numbers of patients can be accrued. The resulting research evaluations can be published in peer-reviewed medical journals...
  77. pmc Motivational readiness for physical activity and quality of life in long-term lung cancer survivors
    Matthew M Clark
    Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, United States
    Lung Cancer 61:117-22. 2008
    ..Physical activity level may have important QOL and symptom management benefits for long-term lung cancer survivors...
  78. pmc Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer
    Evanthia Galanis
    Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 16:979-84. 2008
    ..5 months from treatment initiation. Rexin-G is well tolerated in doses up to 6 x 10(11) CFU in patients with recurrent pancreatic cancer, but there was no evidence of clinical antitumor activity...
  79. ncbi request reprint Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management
    Anne Kanard
    Department of Oncology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Support Oncol 2:127-32; discussion 133-5, 138-40. 2004
    ..This review provides a summary of the factors that may contribute to cognitive decline in this group of patients and comments upon how cognitive dysfunction or the risk for it might influence patient management...
  80. ncbi request reprint Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly
    Steven E Schild
    Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 103:2349-54. 2005
    ..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial...
  81. ncbi request reprint Symptom control trials: a 20-year experience
    Charles L Loprinzi
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Support Oncol 5:119-25, 128. 2007
    ....
  82. doi request reprint Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians
    Richa Sood
    Division of General Internal Medicine, Women s Health Clinic, Mayo Clinic, Rochester, MN 55905, USA
    J Am Board Fam Med 24:202-10. 2011
    ..The goal of this review is to present an overview of the available research evidence on BCHT, dispel myths about the use of compounded hormones, and provide helpful tips to answer commonly asked questions about BCHT...
  83. ncbi request reprint Non-traumatic vertebral fractures in patients with locally advanced esophageal cancer: a previously unreported, unrecognized problem
    H McKean
    Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 20:102-6. 2007
    ..If confirmed, future studies should focus on identifying risk factors and optimal strategies for the prevention and treatment of vertebral fractures in patients with esophageal cancer...
  84. doi request reprint Bone pain from granulocyte colony stimulating factor: does clinical trial sponsorship by a pharmaceutical company influence its reporting?
    Y Aldairy
    Division of Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Cancer Care (Engl) 20:72-6. 2011
    ..The reporting of adverse events from cancer symptom control and palliative care interventions should be improved - especially in trials not sponsored by pharmaceutical companies...
  85. ncbi request reprint Weight gain does not preclude increased ubiquitin conjugation in skeletal muscle: an exploratory study in tumor-bearing mice
    A Jatoi
    Department of Oncology, Mayo Clinic, Rochester, Minn 55455, USA
    Ann Nutr Metab 45:116-20. 2001
    ..At least 13 studies have shown that the ubiquitin-proteasome system mediates muscle wasting in weight-losing cancer subjects. We hypothesized that cancer itself may activate the ubiquitin-proteasome system, regardless of weight loss...
  86. doi request reprint Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005)
    Michele M Corsini
    Department of Radiation Oncology the Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:3511-6. 2008
    ..To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic adenocarcinoma...
  87. ncbi request reprint Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?
    Aminah Jatoi
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 30:72-5. 2003
    ....
  88. pmc Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report
    Farrah J Mateen
    Department of Neurology, Mayo Clinic, Rochester, MN, USA
    Psychooncology 17:721-5. 2008
    ..Patients with schizophrenia sometimes receive substandard medical care. This study explored such disparities among lung cancer patients with underlying schizophrenia...
  89. ncbi request reprint Glutamine does not prevent paclitaxel-associated myalgias and arthralgias
    Stacy D Jacobson
    Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Support Oncol 1:274-8. 2003
    ..96). Thus this trial did not suggest any role for oral glutamine, compared with placebo, for preventing the development, or alleviating the severity, of paclitaxel-induced myalgias/arthralgias...
  90. ncbi request reprint Curing patients with locally advanced esophageal cancer: an update on multimodality therapy
    K P McKian
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Dis Esophagus 19:448-53. 2006
    ..This review discusses recent studies in this field and outlines promising versus less promising therapeutic strategies...
  91. ncbi request reprint Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4)
    Michele Y Halyard
    Mayo Clinic, Scottsdale, AZ, USA
    Int J Radiat Oncol Biol Phys 67:1318-22. 2007
    ..This multi-institutional, double-blind, placebo-controlled trial was conducted to provide definitive evidence of this mineral's palliative efficacy...
  92. ncbi request reprint Parosteal osteosarcoma from a rib
    A Jatoi
    The Lung Tumor Evaluation Center, New England Medical Center, Tufts University, Boston, Massachusetts, USA
    Ann Thorac Surg 65:265-7. 1998
    ..Rib parosteal osteosarcomas are even rarer, with only 2 cases in the literature. We report a third such case, with a 32-month disease-free survival. Issues relevant to the management of rib parosteal osteosarcomas are discussed...
  93. ncbi request reprint Does dietary counseling improve quality of life in cancer patients? A systematic review and meta-analysis
    Thorvardur R Halfdanarson
    Department of Internal Medicine, Division of Hematology, Oncology and Blood and Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City, USA
    J Support Oncol 6:234-7. 2008
    ..56 (95% confidence interval,-0.01-1.14; P = 0.06). Dietary counseling does not appear to improve QOL significantly in patients with cancer. However,an observed trend toward benefit underscores the need for further study...
  94. ncbi request reprint Current management strategies for ovarian cancer
    Giovanni D Aletti
    Division of Gynecologic Surgery, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:751-70. 2007
    ..In this review, we provide an overview of ovarian cancer with particular emphasis on recent advances in operative management and systemic therapies...
  95. ncbi request reprint Who should receive parenteral nutrition or pharmacologic therapy for loss of appetite and weight in the setting of incurable cancer?
    Aminah Jatoi
    Curr Opin Support Palliat Care 1:279-80. 2007
  96. ncbi request reprint Why do oncologists prescribe--or not prescribe--conventional chemotherapy to geriatric patients with metastatic non-small cell lung cancer?
    Aminah Jatoi
    J Support Oncol 4:311-2. 2006
  97. ncbi request reprint New agents, new rashes: an update on skin complications from cancer chemotherapy
    Smitha Patiyil
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Oncol Rep 8:269-74. 2006
    ..It also embarks on a brief discussion of issues that investigators must face when designing clinical trials aimed at rash palliation...
  98. ncbi request reprint Adenosine triphosphate: does it help cancer patients "get bigger and stronger"?
    Aminah Jatoi
    J Clin Oncol 20:362-3. 2002
  99. ncbi request reprint Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment
    Aminah Jatoi
    Department of Oncology, Mayo Comprehensive Cancer Center, Mayo Clinic Foundation, Rochester, MN, USA
    Semin Radiat Oncol 12:62-7. 2002
    ..An ongoing phase 2 trial by the North Central Cancer Treatment Group (NCCTG) may help clarify a role for cytoprotectants in patients receiving combined-modality therapy for esophageal cancer...

Research Grants9

  1. Creatine: Is It a Body Builder for Cancer Patients?
    Aminah Jatoi; Fiscal Year: 2004
    ..obtain longitudinal toxicity and quality of life data on this same cohort of 50 patients and will make direct comparisons between treatment arms on toxicity incidence and severity and on maximal quality of life scores ..
  2. Wine for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2010
    ..3. To explore whether wine in combination with megestrol acetate alters the hormonal milieu that modulates appetite. We will specifically look for alterations of circulating leptin, ghrelin, and neuropeptide y. ..
  3. Neuropeptide Y for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2003
    ..These two pilot studies will allow us to lay the groundwork for such larger trials. Our ultimate goal is to help cancer patients who suffer from anorexia. ..
  4. Mechanisms and Therapeutics in Cancer Anorexia/Cachexia
    Aminah Jatoi; Fiscal Year: 2004
    ..This K23 grant application will serve as a springboard to allow her to delve into the pathophysiology of this syndrome and to develop into an independent clinical investigator. ..
  5. Wine for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2007
    ..3. To explore whether wine in combination with megestrol acetate alters the hormonal milieu that modulates appetite. We will specifically look for alterations of circulating leptin, ghrelin, and neuropeptide y. ..
  6. Wine for Cancer-Associated Anorexia
    Aminah Jatoi; Fiscal Year: 2009
    ..3. To explore whether wine in combination with megestrol acetate alters the hormonal milieu that modulates appetite. We will specifically look for alterations of circulating leptin, ghrelin, and neuropeptide y. ..